Pyrazinamide
- Generic Name
- Pyrazinamide
- Brand Names
- Rifater, Tebrazid
- Drug Type
- Small Molecule
- Chemical Formula
- C5H5N3O
- CAS Number
- 98-96-4
- Unique Ingredient Identifier
- 2KNI5N06TI
- Background
A pyrazine that is used therapeutically as an antitubercular agent.
- Indication
For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
- Associated Conditions
- Active Tuberculosis, Pulmonary Tuberculosis (TB)
Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
- Conditions
- HIVTuberculosis
- Interventions
- Dietary Supplement: Pyridoxine (vitamin B6)
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 104
- Registration Number
- NCT04311502
- Locations
- 🇭🇹
Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti
🇿🇼Milton Park CRS, Harare, Zimbabwe
🇿🇦CAPRISA eThekwini CRS, Durban, Kwa Zulu Natal, South Africa
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis
- Conditions
- Tuberculosis, PulmonaryTuberculosis, Multidrug-ResistantTuberculosisTuberculosis, MDRDrug-Resistant Tuberculosis
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 26
- Registration Number
- NCT04179500
- Locations
- 🇿🇦
CHRU, Sizwe Tropical Diseases Hospital, Johannesburg, South Africa
🇿🇦Isango Lethemba TB Research Unit Empilweni TB Hospital, Port Elizabeth, South Africa
🇿🇦The Aurum Institute: Rustenburg Clinical Research Centre, Rustenburg, South Africa
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
- Conditions
- TuberculosisPre-XDR-TBExtensively Drug-Resistant TuberculosisMulti Drug Resistant TuberculosisRifampicin Resistant Tuberculosis
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Wits Health Consortium (Pty) Ltd
- Target Recruit Count
- 402
- Registration Number
- NCT04062201
- Locations
- 🇿🇦
Jose Pearson TB Hospital, Port Elizabeth, Eastern Cape, South Africa
🇿🇦King DinuZulu Hospital Complex, Durban, KwaZulu Natal, South Africa
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University College, London
- Target Recruit Count
- 675
- Registration Number
- NCT03474198
- Locations
- 🇮🇩
Saiful Anwar Hospital, Malang, Indonesia
🇺🇬Joint Clinical Research Centre, Mbarara, Uganda
🇺🇬Infectious Diseases Institute, Kampala, Uganda
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
- Conditions
- Tuberculosis, PulmonaryTuberculosis, Multidrug-ResistantTuberculosis, MDRTuberculosisDrug-Resistant Tuberculosis
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Global Alliance for TB Drug Development
- Target Recruit Count
- 455
- Registration Number
- NCT03338621
- Locations
- 🇿🇦
University of Cape Town Lung Institute, Cape Town, South Africa
🇿🇦Madibeng Centre for Research, Brits, South Africa
🇿🇦CHRU, Empilweni TB Hospital, Port Elizabeth, South Africa
Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin
- Conditions
- Tuberculosis Multi Drug Resistant Active
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Boston University
- Registration Number
- NCT02975570
Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 3900
- Registration Number
- NCT02901288
- Locations
- 🇨🇳
The Infectious Hospital of Hebi, Hebi, Henan, China
🇨🇳Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China
🇨🇳Anhui Chest Hospital, Hefei, Anhui, China
Evaluating Newly Approved Drugs for Multidrug-resistant TB
- Conditions
- Tuberculosis, Multidrug-ResistantInfection, BacterialPulmonary Tuberculoses
- Interventions
- Drug: Control arm MDR-TB regimen, consistent with WHO guidelines
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Médecins Sans Frontières, France
- Target Recruit Count
- 754
- Registration Number
- NCT02754765
- Locations
- 🇰🇿
City Centre of Phthisiopulmonology, Almaty, Kazakhstan
🇵🇰The Indus Hospital, Karachi, Pakistan
🇰🇿Center of Phthisiopulmonology of Almaty Health Department, Almaty, Kazakhstan
Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers
- First Posted Date
- 2016-03-07
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 12
- Registration Number
- NCT02700347
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore, Singapore
Treatment Shortening of MDR-TB Using Existing and New Drugs
- Conditions
- Tuberculosis, Multidrug-Resistant
- Interventions
- Drug: Locally-used WHO-approved MDR-TB regimen in Korea
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 214
- Registration Number
- NCT02619994
- Locations
- 🇰🇷
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.